Novo Nordisk's drug sales boosted by virus-related stockpiling

The world's top maker of diabetes drugs Novo Nordisk beat profit and sales forecasts in the first quarter and kept its full-year outlook as diabetics stocking up during the coronavirus pandemic led to a surge in demand for its medicines.